Trials / No Longer Available
No Longer AvailableNCT06331832
Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL
Treatment Guidelines for Expanded Access of Imvotamab (IGM-2323) in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas From IGM-2323-001
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- IGM Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IGM2323 | Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε. |
Timeline
- First posted
- 2024-03-26
- Last updated
- 2024-03-26
Locations
3 sites across 3 countries: Australia, South Korea, Spain
Source: ClinicalTrials.gov record NCT06331832. Inclusion in this directory is not an endorsement.